Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  • STATUS
    Recruiting
  • End date
    Jun 30, 2025
  • participants needed
    49
  • sponsor
    National Cancer Institute (NCI)
Updated on 12 September 2021
platelet count
cancer
corticosteroids
ascites
stem cell transplantation
graft versus host disease
total body irradiation
lymphoma
hodgkin's disease
metastatic disease
nitrosoureas
tumor markers
cytokines
measurable disease
interferon
growth factor
pleural effusion
stem cell infusion
bone marrow procedure
glomerular filtration rate
hematopoietic growth factors
cytotoxic chemotherapy
metastasis
neutrophil count
blood transfusion
cancer treatment
nitrosourea
chemotherapeutic agents
interleukins
cancer therapy
antineoplastic
solid tumour
solid tumor
palbociclib
blood count
match treatment
radiopharmaceutical therapy
antibody therapy
cns tumors
platelet transfusion
radiopharmaceutical
131i-mibg
iobenguane
autologous stem cell infusion
pegfilgrastim
myelosuppressive chemotherapy
donor lymphocyte infusion
cellular therapy
platelet transfusions
anti-cancer agents
cns tumor
pleural effusions
bone marrow infiltration

Summary

This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Description

PRIMARY OBJECTIVE:

I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in cell cycle genes.

SECONDARY OBJECTIVES:

I. To estimate the progression free survival in pediatric patients treated with palbociclib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in alterations in cell cycle genes.

II. To obtain information about the tolerability of palbociclib in children and adolescents with relapsed or refractory cancer.

EXPLORATORY OBJECTIVE:

I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).

OUTLINE

Patients receive palbociclib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Details
Condition Advanced Solid Tumor, Recurrent Malignant Glioma, Refractory Non Hodgkin Lymphoma, Advanced Malignant Solid Neoplasm, Recurrent Glioma, Recurrent Osteosarcoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Medulloblastoma, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Recurrent Malignant Germ Cell Tumor, Refractory Ependymoma, RB1 Positive, Recurrent Kidney Wilms Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Treatment laboratory biomarker analysis, pharmacological study, Palbociclib
Clinical Study IdentifierNCT03526250
SponsorNational Cancer Institute (NCI)
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621I based on the presence of an actionable mutation
In addition to the actionable mutations, positive Rb expression by immunohistochemistry is required for study enrollment
Patients must have a body surface area >= 0.87 m^2 at enrollment
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice
Note: The following do not qualify as measurable disease
Malignant fluid collections (e.g., ascites, pleural effusions)
Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma
Elevated tumor markers in plasma or cerebrospinal fluid (CSF)
Previously radiated lesions that have not demonstrated clear progression post radiation
Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment
>= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil counts [ANC] counts): >= 7 days after the last dose of agent
Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
Stem cell infusions (with or without total body irradiation [TBI])
Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)
Autologous stem cell infusion including boost infusion: >= 42 days
Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone morrow (BM) radiation
Note: Radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy
Patients must not have received prior exposure to palbociclib, ribociclib, abemaciclib or any other CDK4/6 inhibitors
For patients with solid tumors without known bone marrow involvement
Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows
Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6
Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8
Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1
Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2
Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4
Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L)
Serum albumin >= 2 g/dL
Patients must be able to swallow intact capsules
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines

Exclusion Criteria

Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment; females study participants of child-bearing potential and their partners, should agree to use highly effective forms of contraception for at least 3 weeks after the last dose of palbociclib; male study participants should avoid fathering a child, donating sperm, and should agree to use highly effective forms of contraception for at least 3 months after the last dose of palbociclib
Concomitant medications
Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
CYP3A4 agents: Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Patients who have an uncontrolled infection are not eligible
Patients who have received a prior solid organ transplantation are not eligible
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note